1256751-11-7

Usage

Uses

Used in Pharmaceutical Industry:
Boceprevir-d9 is used as an antiviral agent for the treatment of hepatitis C virus infections. It functions as a specific inhibitor of the NS3 serine protease enzyme, which is crucial for the virus's replication process. By inhibiting this enzyme, Boceprevir-d9 helps to reduce the viral load and supports the body's immune response in combating the infection.
Additionally, Boceprevir-d9 may be used in research applications to study the mechanisms of hepatitis C virus replication and the development of antiviral resistance. Its labeled nature allows for tracking and analysis in various experimental setups, contributing to a better understanding of the virus and the effectiveness of treatment strategies.

Upstream product

• 1373318-85-4 C₂₇H₃₈⁽²⁾H₉N₅O₅ 
• 1373318-83-2 C₂₀H₂₆⁽²⁾H₉N₃O₄ 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 1373318-84-3 C₁₉H₂₄⁽²⁾H₉N₃O₄ 

Relevant academic research and scientific papers

Synthesis of [14C]boceprevir, [13C 3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor

Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor for HCV treatment. [14C]Boceprevir (SCH 503034, trade name Victrelis) was synthesized from K14CN in 11 steps with an overall yield of 16.4%. [13C3]Boceprevir was synthesized in 16 steps with a 2.5% overall yield. The carbon-13 in the molecule was distributed along the peptide chain. [D9]Boceprevir was synthesized from [D9]-t- butylamine in four steps with an overall yield of 69%. Copyright 2012 John Wiley & Sons, Ltd. Boceprevir is an HCV NS3 protease inhibitor for HCV treatment. [14C]Boceprevir (SCH 503034, trade name Victrelis) was synthesized from K14CN in 11 steps with an overall yield of 16.4%. [13C3] Boceprevir was synthesized in 16 steps with a 2.5% overall yield. The carbon-13 in the molecule was distributed along the peptide chain. [D9]Boceprevir was synthesized from [D9]-t-butylamine in 4 steps with an overall yield of 69%.